NeuroMetrix Inc - Asset Resilience Ratio
NeuroMetrix Inc (NURO) has an Asset Resilience Ratio of 76.14% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NeuroMetrix Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how NeuroMetrix Inc's Asset Resilience Ratio has changed over time. See NeuroMetrix Inc (NURO) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down NeuroMetrix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NURO market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.67 Million | 76.14% |
| Total Liquid Assets | $11.67 Million | 76.14% |
Asset Resilience Insights
- Very High Liquidity: NeuroMetrix Inc maintains exceptional liquid asset reserves at 76.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NeuroMetrix Inc Industry Peers by Asset Resilience Ratio
Compare NeuroMetrix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for NeuroMetrix Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for NeuroMetrix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 76.14% | $11.67 Million | $15.32 Million | +0.22pp |
| 2023-12-31 | 75.92% | $16.27 Million | $21.42 Million | +7.23pp |
| 2022-12-31 | 68.69% | $16.95 Million | $24.67 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $24.89 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $9.60 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.28 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $16.03 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.40 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $10.80 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $10.88 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $14.22 Million | -- |
| 2009-12-31 | 18.48% | $7.50 Million | $40.57 Million | -5.41pp |
| 2008-12-31 | 23.89% | $7.50 Million | $31.38 Million | -16.24pp |
| 2007-12-31 | 40.13% | $22.62 Million | $56.37 Million | -18.05pp |
| 2006-12-31 | 58.18% | $32.41 Million | $55.71 Million | +2.04pp |
| 2005-12-31 | 56.14% | $24.08 Million | $42.90 Million | +7.20pp |
| 2004-12-31 | 48.94% | $18.57 Million | $37.95 Million | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more